|Mr. Hany Massarany||CEO, Pres & Director||1M||N/A||1961|
|Mr. Scott Mendel||Chief Operating Officer||530.88k||N/A||1967|
|Mr. James B. McNally||Sr. VP of Marketing & Bus. Devel.||414.03k||N/A||1980|
|Mr. Michael Gleeson||Sr. VP of Corp. & Strategic Accounts||403.76k||N/A||1975|
|Mr. Brian Andrew Mitchell||Sr. VP of Operations||381.51k||N/A||1965|
GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
GenMark Diagnostics, Inc.’s ISS Governance QualityScore as of October 4, 2019 is 6. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 6; Compensation: 7.